135,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
68 °P sammeln
  • Gebundenes Buch

Since its introduction as a new clinical entity in 1992, the Brugada syndrome has attracted great interest because of its high incidence in many parts of the world and its association with high risk for sudden death in infants, children and young adults. Recent years have witnessed an exponential rise in the number of reported cases and a striking proliferation of papers serving to define the clinical, genetic, cellular, ionic and molecular aspects of the disease. This text delineates the diagnostic criteria for the syndrome and deals with risk stratification and approaches to therapy. The…mehr

Produktbeschreibung
Since its introduction as a new clinical entity in 1992, the Brugada syndrome has attracted great interest because of its high incidence in many parts of the world and its association with high risk for sudden death in infants, children and young adults. Recent years have witnessed an exponential rise in the number of reported cases and a striking proliferation of papers serving to define the clinical, genetic, cellular, ionic and molecular aspects of the disease. This text delineates the diagnostic criteria for the syndrome and deals with risk stratification and approaches to therapy. The book handles this topic in a very comprehensive manner with the clinical, molecular, genetic, and cellular aspects of the Brugada syndrome authored by the leading experts in the field.
Autorenporträt
Charles Antzelevitch, PhD, is Executive Director/Director of Research; Gordon K. Moe Scholar; Professor of Pharmacology at the Masonic Medical Research Laboratory; Utica, New York. Pedro Brugada, MD, PhD, is Professor of Cardiology at the Cardiovascular Center OLV Hospital in Aalst, Belgium.